Drug Prevents Bleeding After Surgery for Gastric Cancer
Proton pump inhibitor more effective than H2-receptor antagonist
THURSDAY, Aug. 9 (HealthDay News) -- A proton pump inhibitor is more effective than an H2-receptor antagonist in preventing delayed bleeding after endoscopy for early gastric cancer, according to the results of a study published in the August issue of the American Journal of Gastroenterology.
Noriya Uedo, M.D., from Osaka Medical Center for Cancer and Cardiovascular Diseases in Japan, and colleagues randomized 143 patients with early gastric cancer to 20 mg rabeprazole (a proton pump inhibitor) or 800 mg cimetidine (an H2-receptor antagonist) starting the day before endoscopic submucosal dissection and continuing for eight weeks.
The researchers found that significantly fewer patients receiving rabeprazole experienced bleeding (adjusted hazard ratio, 0.47).
"Proton pump inhibitor therapy more effectively prevented delayed bleeding from the ulcer created after endoscopic submucosal dissection than did H2-receptor antagonist treatment," Uedo and colleagues conclude.